Certain Factors Could Predict Severe Episodes of Coughing Up Blood in CF Patients, Study Says
Factors such as diabetes, a specific type of fungal infection, and previous mild to moderate episodes of hemoptysis, or coughing up...
Calithera Biosciences’ CB-280 Arginase Inhibitor Trial in Progress Poster Presented at the NACFC
SOUTH SAN FRANCISCO, Calif., Oct. 07, 2020 (GLOBE NEWSWIRE) -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical stage biotechnology...
Lenabasum Fails to Lessen Exacerbations in CF Patients in Phase 2 Trial
A Phase 2 clinical trial of oral lenabasum in people with cystic fibrosis (CF) failed to meet its primary goal of reducing pulmonary...
FDA Grants Approval To Ivacaftor For Treatment Of Cystic Fibrosis In Infants
Study did not meet primary endpoint of reducing rate of pulmonary exacerbations Lenabasum treatment had a favorable safety profile and...
Oral antibiotics are as effective as IV antibiotics for the eradication of PseudomonasOral antibiot
The results of the long-running 'Torpedo' clinical trial investigating two different approaches to the eradication of a serious cystic...
Study Compares Oral and Intravenous Antibiotics for P. aeruginosa Infections in People With CF
Oral antibiotics are just as effective as intravenous (into-the-vein) antibiotics at killing Pseudomonas aeruginosa bacteria in people...
Disease Duration, Flare-ups Affect Mental Health of Non-CF Bronchiectasis Patients, Study Finds
People with non-cystic fibrosis (CF) bronchiectasis are at an increased risk for anxiety and depression, and this risk is associated with...
VERTEX’S CF BLOCKBUSTER TRIKAFTA EFFECTIVE IN KIDS 6 TO 11 YEARS OF AGE
Vertex Pharmaceuticals announced the completion of its Phase III trial of Trikafta in children ages 6 through 11 years with cystic...
A case for improved carrier screening
Expanded carrier screening addresses limitations in historical ethnic-based screenings, including potential racial and ethnic bias....
Vertex to Seek Expanded FDA Approval for Trikafta After Positive Child Safety Data
Trikafta (elexacaftor/tezacaftor/ivacaftor and ivacaftor) is safe for use in children with cystic fibrosis (CF) as young as age 6, data...
